CLINICAL TRIALS PROFILE FOR HYCAMTIN
✉ Email this page to a colleague
All Clinical Trials for HYCAMTIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002913 ↗ | Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | 1996-12-01 | Phase I trial to study the effectiveness of paclitaxel, cisplatin, and topotecan with or without filgrastim in treating patients who have newly diagnosed stage III or stage IV epithelial ovarian cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy |
| NCT00003415 ↗ | Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome | Completed | University of Arizona | Phase 1/Phase 2 | 1998-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus topotecan in treating patients with myelodysplastic syndrome. |
| NCT00003733 ↗ | Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer | Unknown status | SmithKline Beecham | Phase 2 | 1997-12-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of sequential chemotherapy in treating patients with residual disease following surgery for stage IIB, stage III, or stage IV ovarian cancer. |
| NCT00003958 ↗ | Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma | Completed | National Cancer Institute (NCI) | Phase 3 | 2002-09-01 | This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma. |
| NCT00003958 ↗ | Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma | Completed | Children's Oncology Group | Phase 3 | 2002-09-01 | This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYCAMTIN
Condition Name
Clinical Trial Locations for HYCAMTIN
Trials by Country
Clinical Trial Progress for HYCAMTIN
Clinical Trial Phase
Clinical Trial Sponsors for HYCAMTIN
Sponsor Name
